Evidence map›Paper›PMID 36627464›Full record

ArticleJournal of cancer survivorship : research and practice2023

Mobile health (mHealth) interventions in prostate cancer survivorship: a scoping review.

Motolani E Ogunsanya, Munjireen Sifat, Olufikayo O Bamidele, Elochukwu F Ezenwankwo, Shari Clifton, Chelsea Ton, Jennifer M Knight, Folakemi T Odedina, Joseph A Greer, Kathleen Dwyer and 1 more

Open access · greenAbstract readScoping Review
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Motolani E OgunsanyaCollege of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Motolani-ogunsanya@ouhsc.edu.
Munjireen SifatTSET Health Promotion Research Center, Stephenson Cancer Center, Oklahoma City, OK, USA.
Olufikayo O BamideleHull York Medical School, University of Hull, Cottingham Road, Hull, HU6 7RX, UK.
Elochukwu F EzenwankwoFaculty of Health and Life Sciences, University of Hertfordshire, Hatfield, UK.
Shari CliftonHealth Sciences Library & Information Management, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Chelsea TonCollege of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Jennifer M KnightDepartments of Psychiatry, Medicine, and Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, WI, USA.
Folakemi T OdedinaCenter for Health Equity & Community Engagement Research, Mayo Clinic Florida, Jacksonville, FL, USA.
Joseph A GreerCenter for Psychiatric Oncology & Behavioral Sciences, Massachusetts General Hospital, Boston, MA, USA.
Kathleen DwyerCollege of Nursing, University of Oklahoma, Oklahoma City, OK, USA.
Darla E KendzorTSET Health Promotion Research Center, Stephenson Cancer Center, Oklahoma City, OK, USA.
University of Oklahoma Health Sciences Center · USMassachusetts General Hospital · USMayo Clinic in Florida · USMedical College of Wisconsin · USOU Health Stephenson Cancer CenterUniversity of Hertfordshire · GBUniversity of Hull · GBUniversity of Oklahoma · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Wade Williams · 2018 to 2026
$27.1M
Addressing Health Disparities among Oklahoma Minority and Rural Communities through Clinical Research Education and Career DevelopmentR25MD011564 · NIMHD · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HOUCHEN, COURTNEY WAYNE, STAVRAKIS, STAVROS · 2017 to 2021
$2.7M
NCI NIH HHS P30 CA225520NIMHD NIH HHS R25MD011564
6 · The paper itself

Abstract

purposeThis scoping review explores the application of mHealth technology in prostate cancer (CaP) management along the survivorship continuum.

methodsThe scoping review was conducted using the five-step framework developed by Arksey and O'Malley. Using predefined criteria, we screened citations from Embase, EBSCOHost, Cochrane Library, PubMed, ProQuest, SCOPUS, and Web of Science for primary studies published before December 2021. We selected studies that explored the application of mHealth technology in CaP management and survivorship. Evidence from 14 eligible studies was summarized using narrative synthesis.

resultsFourteen studies published between 2015 and 2021 were included. Ten mHealth apps were identified with only one still in use. Most apps were explored for their supportive care roles during radiotherapy (n = 9) and androgen deprivation therapy (ADT) (n = 1) treatment, mainly to assess outcomes (n = 1) and manage patient-reported symptoms (n = 5). One study deployed mHealth to facilitate recovery after surgery. Very few studies (n = 3) applied mHealth for lifestyle management (i.e., physical activity). Barriers to app usage included connectivity issues, end-user familiarity with the app, login hurdles, and time constraints. Facilitators of app usage included apps being downloaded for participants, devices provided for participants, and the ability to connect with providers through the platform. CONCLUSIONS AND IMPLICATIONS FOR CANCER SURVIVORS: The improving survival rates from CaP suggest that men are now living longer with unfavorable treatment side effects such as reduced sexual functioning, pain, and fatigue. Hence, mHealth represents new hope in men's illness trajectory. However, current application in patients' care pathways remains poor, particularly in the active phase of CaP management. Efforts must be accelerated to explore individual and healthcare-level drivers of mHealth use. The feasibility and descriptive nature of current studies point to a lack of attention to actual implementation and scale-up issues in research considering mHealth application in CaP, hence accounting partly for the gap in research/practice.

Indexed as

Cancer SurvivorsMobile ApplicationsProstatic NeoplasmsTelemedicineAndrogen AntagonistsHumansMaleProstateSurvivorshipAndrogen Antagonists

Identifiers

PMID36627464
PMCPMC13014381
OpenAlexW4315487619

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.